|
|
 | | | |
- close
- close
- close
- close
QUOTE AND NEWS
Market Intelligence Center
Apr 2
Comment
Nuvasive (NASDAQ: NUVA) closed Friday's trading session at $16.84. In the past year, the stock has hit a 52-week low of $11.02 and 52-week high of $34.91. Nuvasive (NUVA) stock has been showing support around $16.52 and resistance in the $17.32...
Market Intelligence Center
Mar 27
Comment
Nuvasive (NASDAQ:NUVA) closed Monday's winning trading session at $17.56. In the past year, the stock has hit a 52-week low of $11.02 and 52-week high of $34.91. Nuvasive (NUVA) stock has been showing support around $16.19 and resistance in the...
MarketWatch
Mar 13
Comment
Basketball great Bill Walton wanders the halls at California investment conference looking for the next great stock he can get passionate about.
Benzinga
Mar 9
Comment
Goldman Sachs raises its price target $2 to $16 on Neutral-rated NuVasive (NASDAQ: NUVA) as the company continues to execute in what is an increasingly difficult end-user market.
Goldman Sachs says, "4Q2011 results showed market share...
Market Intelligence Center
Mar 5
Comment
Nuvasive (NASDAQ: NUVA) closed Friday's trading session at $15.61. In the past year, the stock has hit a 52-week low of $11.02 and 52-week high of $34.91. Nuvasive (NUVA) stock has been showing support around $15.32 and resistance in the $15.94...
Marketwire
Mar 1
Comment
SAN DIEGO, CA -- (Marketwire) -- 03/01/12 -- NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that the Company will participate in
Market Intelligence Center
Feb 15
Comment
Nuvasive (NASDAQ:NUVA) closed Tuesday's seesaw trading session at $15.58. In the past year, the stock has hit a 52-week low of $11.02 and 52-week high of $34.91. Nuvasive (NUVA) stock has been showing support around $14.83 and resistance in the...
Benzinga
Jan 26
Comment
(c) 2011 Benzinga.com. All rights reserved. This material may not be published in its entirety or redistributed without the approval of Benzinga.
Benzinga
Jan 26
Comment
BMO Capital Markets reiterates its perform rating on Nuvasive (NASDAQ: NUVA) and raises its price target to $16 (previously $14) as a worst-case scenario on injunction case appears to be unlikely for now. developments.
BMO Capital Markets...
StreetInsider.com
Jan 26
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Medtronic+%28MDT%29+Injunction+Against+NuVasive+%28NUVA%29+Tentatively+Denied+in+San+Diego+Court/7109298.html for the full story.
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSISNuVasive, Inc. is a medical device company that designs and develops products for improved surgical treatment of spinal disorders. It's surgery platform, termed Maximum Access Surgery, allows for minimally disruptive surgeries through use of NeuroVision, their software-driven nerve avoidance system, and MaXcess, a split-blade retraction system for spinal access.
References
| |||||||
